Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research.

Carney G, Maclure M, Bassett K, Taylor S, Dormuth CR.

Pharmacoepidemiol Drug Saf. 2019 Dec 2. doi: 10.1002/pds.4926. [Epub ahead of print]

PMID:
31793135
2.

Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example.

Secrest MH, Platt RW, Reynier P, Dormuth CR, Benedetti A, Filion KB.

Pharmacoepidemiol Drug Saf. 2019 Sep 4. doi: 10.1002/pds.4876. [Epub ahead of print]

PMID:
31486165
3.

A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns.

Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, Filion KB.

Pharmacoepidemiol Drug Saf. 2019 Aug 28. doi: 10.1002/pds.4878. [Epub ahead of print]

PMID:
31464069
4.

Influence of opioid prescribing standards on drug use among patients with long-term opioid use: a longitudinal cohort study.

Morrow RL, Bassett K, Wright JM, Carney G, Dormuth CR.

CMAJ Open. 2019 Jul 25;7(3):E484-E491. doi: 10.9778/cmajo.20190003. Print 2019 Jul-Sep.

5.

Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia.

Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR.

Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1067-1076. doi: 10.1002/pds.4804. Epub 2019 Jul 3.

6.

A theoretical exploration of therapeutic monomania as a physician-based instrumental variable.

Potter BJ, Dormuth C, Le Lorier J.

Pharmacoepidemiol Drug Saf. 2019 May 15. doi: 10.1002/pds.4757. [Epub ahead of print]

PMID:
31094048
7.

Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study.

Morrow RL, Bassett K, Maclure M, Dormuth CR.

BMJ Open. 2019 May 5;9(5):e025567. doi: 10.1136/bmjopen-2018-025567.

8.

Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits.

Morrow RL, Dormuth CR, Paterson M, Mamdani MM, Gomes T, Juurlink DN; Canadian Drug Safety Effectiveness Research Network (CDSERN).

BMJ Open. 2019 Mar 13;9(3):e026705. doi: 10.1136/bmjopen-2018-026705.

10.

Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research.

Secrest MH, Platt RW, Dormuth CR, Chateau D, Targownik L, Nie R, Doyle CM, Dell'Aniello S, Filion KB.

Pharmacoepidemiol Drug Saf. 2019 Jan 9. doi: 10.1002/pds.4708. [Epub ahead of print]

PMID:
30628152
11.

Long-Term Use of Proton Pump Inhibitors and Community-Acquired Pneumonia: Adverse Effect or Bias?

Ayele HT, Dormuth CR, Filion KB.

J Am Geriatr Soc. 2018 Dec;66(12):2427-2428. doi: 10.1111/jgs.15575. Epub 2018 Oct 16. No abstract available.

PMID:
30325006
12.

Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug-safety article.

Gamble JM, Traynor RL, Gruzd A, Mai P, Dormuth CR, Sketris IS.

Pharmacoepidemiol Drug Saf. 2018 Mar 24. doi: 10.1002/pds.4401. [Epub ahead of print]

PMID:
29575351
13.

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.

Jun M, Lix LM, Durand M, Dahl M, Paterson JM, Dormuth CR, Ernst P, Yao S, Renoux C, Tamim H, Wu C, Mahmud SM, Hemmelgarn BR; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.

BMJ. 2017 Oct 17;359:j4323. doi: 10.1136/bmj.j4323.

14.

Correction: Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis-A Meta-Analysis.

Fisher A, Bassett K, Goel G, Stanely D, Brookhart MA, Freeman HJ, Wright JM, Dormuth CR.

PLoS One. 2017 Feb 15;12(2):e0172646. doi: 10.1371/journal.pone.0172646. eCollection 2017.

15.

Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.

Fisher A, Carney G, Bassett K, Dormuth CR.

Drugs Aging. 2017 Mar;34(3):221-231. doi: 10.1007/s40266-017-0438-x.

PMID:
28138912
16.

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.

Fisher A, Bassett K, Goel G, Stanely D, Brookhart MA, Freeman HR, Wright JM, Dormuth CR.

PLoS One. 2016 Dec 8;11(12):e0168005. doi: 10.1371/journal.pone.0168005. eCollection 2016. Erratum in: PLoS One. 2017 Feb 15;12 (2):e0172646.

17.

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol.

Holbrook A, Dormuth C, Morrow R, Lee A, Troyan S, Li G, Pullenyegum E.

BMJ Open. 2016 Nov 24;6(11):e013263. doi: 10.1136/bmjopen-2016-013263.

18.

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Suissa S, Dormuth CR, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, Paterson JM, LeLorier J, Levy AR, Ernst P, Platt RW, Sketris IS.

JAMA Intern Med. 2016 Oct 1;176(10):1464-1473. doi: 10.1001/jamainternmed.2016.1522.

PMID:
27479930
19.

Observational Studies of Drug Safety in Multi-Database Studies: Methodological Challenges and Opportunities.

Platt RW, Dormuth CR, Chateau D, Filion K.

EGEMS (Wash DC). 2016 May 18;4(1):1221. doi: 10.13063/2327-9214.1221. eCollection 2016.

20.

Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.

Henry D, Dormuth C, Winquist B, Carney G, Bugden S, Teare G, Lévesque LE, Bérard A, Paterson JM, Platt RW; CNODES (Canadian Network for Observational Drug Effect Studies) Investigators.

CMAJ. 2016 Jul 12;188(10):723-730. doi: 10.1503/cmaj.151243. Epub 2016 Apr 25.

21.

Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.

Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P; Canadian Network for Observational Drug Effect Studies (CNODES) investigators.

Br J Clin Pharmacol. 2016 Aug;82(2):461-72. doi: 10.1111/bcp.12964. Epub 2016 May 19.

22.

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.

Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P; CNODES Investigators.

N Engl J Med. 2016 Mar 24;374(12):1145-54. doi: 10.1056/NEJMoa1506115.

23.

Head to head comparison of the propensity score and the high-dimensional propensity score matching methods.

Guertin JR, Rahme E, Dormuth CR, LeLorier J.

BMC Med Res Methodol. 2016 Feb 19;16:22. doi: 10.1186/s12874-016-0119-1.

24.

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies Investigators.

BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581.

25.

Likelihood ratio meta-analysis: New motivation and approach for an old method.

Dormuth CR, Filion KB, Platt RW.

Contemp Clin Trials. 2016 Mar;47:259-65. doi: 10.1016/j.cct.2016.01.008. Epub 2016 Feb 4.

26.

Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities.

Cameron C, Fireman B, Hutton B, Clifford T, Coyle D, Wells G, Dormuth CR, Platt R, Toh S.

Syst Rev. 2015 Nov 5;4:147. doi: 10.1186/s13643-015-0133-0.

27.

Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.

Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P; Canadian Network of Observational Drug Effect Studies (CNODES) Investigators.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1716-22. doi: 10.2215/CJN.11271114. Epub 2015 Jul 31.

28.

Seasonal effects on the occurrence of nocturnal leg cramps: a prospective cohort study.

Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM.

CMAJ. 2015 Mar 3;187(4):248-253. doi: 10.1503/cmaj.140497. Epub 2015 Jan 26.

29.

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman HJ, Dormuth CR.

BMJ Open. 2014 Sep 30;4(9):e005532. doi: 10.1136/bmjopen-2014-005532.

30.

Time course for blood pressure lowering of dihydropyridine calcium channel blockers.

Ghamami N, Chiang SH, Dormuth C, Wright JM.

Cochrane Database Syst Rev. 2014 Aug 31;(8):CD010052. doi: 10.1002/14651858.CD010052.pub2. Review.

PMID:
25173808
31.

Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR.

PLoS One. 2014 Aug 20;9(8):e105193. doi: 10.1371/journal.pone.0105193. eCollection 2014.

32.

Author's reply to Phillips and Brugts.

Dormuth CR.

BMJ. 2014 Jul 30;349:g4890. doi: 10.1136/bmj.g4890. No abstract available.

PMID:
25078143
33.

Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study.

Cadarette SM, Lévesque L, Mamdani M, Perreault S, Juurlink DN, Paterson JM, Carney G, Gunraj N, Hawker GA, Tadrous M, Wong L, Dormuth CR.

CMAJ Open. 2013 Sep 13;1(3):E97-E105. doi: 10.9778/cmajo.20130036. eCollection 2013 Sep.

34.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.

Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L; Canadian Network for Observational Drug Effect Studies Investigators.

BMJ. 2014 May 29;348:g3244. doi: 10.1136/bmj.g3244.

35.

Proton pump inhibitors and the risk of adverse cardiac events.

Juurlink DN, Dormuth CR, Huang A, Hellings C, Paterson JM, Raymond C, Kozyrskyj A, Moride Y, Macdonald EM, Mamdani MM.

PLoS One. 2013 Dec 27;8(12):e84890. doi: 10.1371/journal.pone.0084890. eCollection 2013.

36.

Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.

Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare GF, Ravani P, Ernst P, Dormuth CR; CNODES Investigators.

Gut. 2014 Apr;63(4):552-8. doi: 10.1136/gutjnl-2013-304738. Epub 2013 Jul 15.

37.

Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.

Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies.

BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.

38.

Comparative effectiveness of tiotropium and ipratropium in prevention of hospital readmission for COPD: a population-based cohort study.

Kawasumi Y, Paterson MJ, Morrow RL, Miller TA, Bassett K, Wright JM, Dormuth CR.

Clin Ther. 2013 Apr;35(4):523-531.e1. doi: 10.1016/j.clinthera.2012.10.007. Epub 2013 Mar 13.

PMID:
23490290
39.

Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study.

Carney GA, Bassett K, Wright JM, Dormuth CR.

BMJ Open. 2012 Nov 12;2(6). pii: e001910. doi: 10.1136/bmjopen-2012-001910. Print 2012.

40.

Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network.

J Invest Dermatol. 2013 Apr;133(4):907-12. doi: 10.1038/jid.2012.387. Epub 2012 Oct 25.

41.

A randomized trial assessing the impact of a personal printed feedback portrait on statin prescribing in primary care.

Dormuth CR, Carney G, Taylor S, Bassett K, Maclure M.

J Contin Educ Health Prof. 2012 Summer;32(3):153-62. doi: 10.1002/chp.21140.

PMID:
23008077
42.

Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines.

Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network.

CMAJ. 2012 Nov 6;184(16):E852-6. doi: 10.1503/cmaj.120465. Epub 2012 Sep 4.

43.

Algorithms to estimate the beginning of pregnancy in administrative databases.

Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S.

Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):16-24. doi: 10.1002/pds.3284. Epub 2012 May 2.

44.

Statins for primary prevention.

Tejani AM, Musini V, Bassett K, Dormuth C, Perry T, Wright JM.

CMAJ. 2012 Apr 17;184(7):791; author reply 791-2. doi: 10.1503/cmaj.112-2036. No abstract available.

45.

Comparative health-care cost advantage of ipratropium over tiotropium in COPD patients.

Dormuth CR, Yamaguchi J, Wilmer B, Hosick D, Stürmer T, Carney G.

Value Health. 2012 Mar-Apr;15(2):269-76. doi: 10.1016/j.jval.2011.10.014. Epub 2012 Feb 9.

46.

Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children.

Morrow RL, Garland EJ, Wright JM, Maclure M, Taylor S, Dormuth CR.

CMAJ. 2012 Apr 17;184(7):755-62. doi: 10.1503/cmaj.111619. Epub 2012 Mar 5.

47.

CNODES: the Canadian Network for Observational Drug Effect Studies.

Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, Lelorier J, Levy A, Martens PJ, Paterson JM, Platt RW, Sketris I, Teare G; Canadian Network for Observational Drug Effect Studies (CNODES).

Open Med. 2012 Oct 30;6(4):e134-40. Print 2012.

48.

Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis.

Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM.

Arch Intern Med. 2012 Jan 23;172(2):120-6. doi: 10.1001/archinternmed.2011.1029. Epub 2011 Dec 12.

PMID:
22157068
49.

Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.

Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR.

Osteoporos Int. 2012 Apr;23(4):1475-80. doi: 10.1007/s00198-011-1771-2. Epub 2011 Sep 8.

50.

Trends in health care utilization in British Columbia following public coverage for tiotropium.

Dormuth CR, Morrow RL, Carney G.

Value Health. 2011 Jun;14(4):600-6. doi: 10.1016/j.jval.2010.11.018. Epub 2011 May 25.

Supplemental Content

Loading ...
Support Center